Acer Therapeutics Enrolls First Patient in its Phase 2a Clinical Trial of ACER-801 for Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause
30 mars 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Secures up to $48.5 Million in Convertible Note and Secured Loan Financing Facilities
07 mars 2022 06h15 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Reports Q4 and Full Year 2021 Financial Results and Provides Corporate Update
02 mars 2022 17h18 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer
22 févr. 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics to Participate in 2022 BIO CEO & Investor Conference
01 févr. 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for...
Acer Therapeutics and Relief Therapeutics Announce Presentation of Four ACER-001 Posters at the Upcoming SIMD and GMDI Conferences
27 janv. 2022 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF)...
Acer Therapeutics to Participate in January 2022 Virtual Investor Conferences
22 déc. 2021 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics Announces ACER-801 IND Clearance for the Treatment of Induced Vasomotor Symptoms
09 déc. 2021 08h30 HE
|
Acer Therapeutics Inc.
Phase 2a trial initiation expected in Q1 2022 Trial designed to generate proof of concept data for ACER-801 and identify optimal dose for subsequent efficacy trials in patients with iVMS NEWTON,...
Acer Therapeutics Reports Q3 2021 Financial Results and Provides Corporate Update
19 nov. 2021 17h00 HE
|
Acer Therapeutics Inc.
NEWTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
Acer Therapeutics and Relief Therapeutics Announce Issuance of U.S. Patent 11,154,521 Covering ACER-001 Formulation
26 oct. 2021 08h30 HE
|
Acer Therapeutics Inc.
NEWTON, Mass. and GENEVA, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”) and its collaboration partner, RELIEF THERAPEUTICS Holding SA (SIX: RLF,...